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Abstract
Background: By 2033, the number of people aged 85 years and over in the UK is projected to double,
accounting for 5% of the total population. It is important to understand the surgical outcome after a
pancreatic resection in the elderly to assist decision making.
Methods: Over a 9-year period (from January 2000 to August 2009), 428 consecutive patients who
underwent a pancreatic resection were reviewed. Data were collected on mortality, complications, length
of stay and survival. Patients were divided into two groups (younger than 70 and older than 70 years old)
and outcomes were analysed.
Results: In all, 119 (27.8%) patients were  70 years and 309 (72.2%) patients were < 70 years. The
median length of stay for the older and younger group was 15 days (range 3–91) and 14 days (range
3–144), respectively. The overall mortality was 3.4% in the older group and 2.6% in the younger group
(P = 0.75). The older cohort had a cumulative median survival of 57.3 months (range 0–119), compared
with 78.7 months (range 0–126) in the younger cohort (P < 0.0001). In patients undergoing a pancreatic
resection for ductal adenocarcinoma and cholangiocarcinoma there was a significant difference in
survival with P-values of 0.043 and 0.003, respectively. For ampullary adenocarcinoma, the older group
had a median survival of 47.1 months compared with 68.3 months (P = 0.194).
Conclusion: Results from this study suggest that while elderly patients can safely undergo a pancreatic
resection and that age alone should not preclude a pancreatic resection, there is still significant morbidity
and mortality in the octogenarian subgroup with poor long-term survival with the need for quality-of-life
assessment.
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Introduction
The demographics of the UK population are changing with the
fastest change in those aged 85 years and over. By 2033, the
number of people aged 85 years and over is projected to be more
than double, accounting for 5% of the total population.1 Over the
last 30 years the number of centenarians (people aged 100 years or
more) in the UK has increased five-fold from 2500 in 1980 to
12 640 in 2010.2 Similarly, the eldest elderly group are expected to
account for 24% of the elderly population and 5% of the overall
American population by 2050.3
Pancreatic cancer studies show that the age-specific incidence
rates are higher in men from age 40 years onwards and that the
incidence rates rise dramatically from age 65years.4 Pancreatic
cancer risk is very strongly related to age with 85% of patients
being over 60 years at time of diagnosis.4 Therefore, it is important
to understand the surgical outcome in the elderly population to
assist surgical decision making. Over the last decade, outcomes
after a pancreatic resection have improved with most studies
reporting mortality rates of less than 5%.5–7,10,12,23 Recently, studies
have tried to show that age alone should not be a contraindication
to pancreatic resection.12 However, the age groups analysed have
varied among the studies,making it difficult to compare and reach
viable conclusions.8–13
The majority of the studies report statistically higher morbidity
rates in the designated older patients when compared with
younger patients.8–11When analysingmortality, some studies show
no difference8.9,12 whereas other groups report higher mortality in
the older group.11,13
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Studies have shown that almost 40% of the patients referred to
specialist centres fall into the 70 years or older category.8,14 In an
attempt to determine whether pancreatic resection is justified in
elderly patients, this study retrospectively reviewed the pancreatic
resection database of a single tertiary pancreatic unit to compare
outcomes with their younger counterparts with relation to mor-
tality, long-term survival, length of hospital stay and morbidity.
Methods
Study population
Over a 9-year period (from January 2000 to August 2009), 428
pancreatic resections were carried out at a single tertiary pancre-
atic unit. They were retrospectively analysed using a prospectively
collected database. The patients were divided into those aged
70 years and older and those younger than 70 years, and the
demographics, post-operative diagnosis, tumour characteristics
and outcomes of the two groups studied were compared. There
was further sub group analysis for malignant cases divided in
decades of < 60, 60–69, 70–79 and >80 years.
The surgical resections studied were: pancreaticoduodenec-
tomy, distal pancreatectomy, subtotal pancreatectomy, total
pancreatectomy, central pancreatectomy, duodenal sparing
pancreatectomy and enucleation.
All pathology specimens were reviewed by a single pathologist
to determine the primary histopathological diagnosis and the
extent of the disease: TNM status, resection margins and portal
vein invasion. This was done using the Leeds standardized Pathol-
ogy Protocol (LEEPP).15,16
Peri-operative mortality was defined as in-hospital death or
death within 30 days of surgery. The specific complications
studied included: delayed gastric emptying, pancreatic fistula for-
mation, intra-abdominal collection, cholangitis, pneumonia,
wound infection, peptic ulceration, upper gastrointestinal bleed-
ing and cardiac events. The complications were divided into five
grades (I to V) according to the Dindo–Clavien classification.17,18
Follow-up
All patients with malignant pathology were followed up on a
6-monthly basis for 3 years and annually thereafter until they had
disease recurrence or died. There was a prospectively collected
follow-up database. These patients had tumour markers checked
at each clinic visit and a computed tomography scan only if they
were elevated or was clinically indicated. Data were also collected
on patients undergoing chemotherapy, whether adjuvant or
palliative.
Statistical analysis
Statistical analyses were carried out using Excel (Microsoft,
Redmond, WA, USA) and XLSTAT (Addinsoft, New York, NY,
USA). The statistical analyses of categorical variables were per-
formed using Fisher’s exact test. Comparisons between different
groups were made using the Mann–Whitney U-test. Survival
curves for the two groups were generated using the Kaplan–Meier
method. Differences in long-term survival between subgroups
were compared using the log-rank test. P-values less than 0.05
were considered significant.
Results
Patient characteristics
Between January 2000 to August 2009, 428 patients underwent a
major pancreatic resection for a variety of malignant and benign
disease. The median age of the entire cohort was 64 years (range
15 to 86). The demographic data, including age, gender, initial
presentation and type of resection, are shown in Table 1. There
was no statistically significant difference in the age, gender, aeti-
ology or type of resection carried out between the two age groups.
Pathology
Of the 119 pancreatic resections performed in the older age group,
100 (84.0%) were for malignant disease compared wuth 230
(74.4%) in the younger group (P = 0.057). The data representing
post-operative pathological diagnosis are shown in Table 2. The
TNM and resection margins status for malignant cases are sum-
marized in Table 3. There was no significant difference between
the two groups with relation to the proportion of node positive
disease or the T stage.
Table 1 Demographic data including age, gender, initial presentation
and type of resection of entire cohort (% in brackets)
Characteristics Younger
than 70
years
Older than
70 years
P-value
Age distribution 309 119
Gender
Male 170 (55) 57 (48) 0.196
Female 139 (45) 62 (52)
Initial Presentation
Jaundice 111 (36) 52 (44) 0.149
Pain and Jaundice 12 (4) 6 (5)
Weight loss 13 (4) 8 (7)
Incidental 26 (8) 16 (13)
Others 50 (16) 12 (10)
Not available 97 (31) 25 (21)
Procedure
Pancreaticoduodenectomy 223 (74) 95 (80) 0.066
Distal pancreatectomy 59 (19) 21 (18)
Total pancreatectomy 5 (2) 0 (0)
Subtotal pancreatectomy 6 (2) 0 (0)
Completion pancreatectomy 2 (1) 0 (0)
Central pancreatectomy 1 (1) 0 (0)
Duodenal Sparing
pancreatectomy
6 (2) 1 (1)
Enucleation 6 (2) 1 (1)
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Morbidity and mortality
Of the 428 patients that underwent a pancreatic resection, 12
died peri-operatively (2.8%). There was no significant difference
between the two age groups when comparing post-operative
morbidity, post-operative mortality and median hospital stay as
shown in Table 4.
Chemotherapy
Table 5 shows the patients who underwent adjuvant or palliative
chemotherapy. Although the difference did not meet statistical
significance, a greater number of younger people underwent
adjuvant chemotherapy than the elderly (19.6% vs. 15%).
Survival analysis
The older cohort had a cumulative median survival of
57.3 months (range 0–119), compared with a median survival of
78.7 months (range 0–126) in the younger cohort (P < 0.001)
as seen in Fig. 1.
Long-term survival was compared between different age
groups. Patients younger than 60 years old (n = 167) had a median
survival time of 79.6 months, between 60 and 69 years old
(n = 143) had a median survival of 73.5 months, and between 70
and 79 years old (n = 102) had a median survival of 48.4 months
and older than 80 years old (n = 16) had a median survival time of
23.8 months.
Survival curves were generated for different age groups
(younger than 60 years old, 60 to 69 years, 70 to 79 years and older
than 80 years old) in patients that underwent a pancreatic resec-
tion for ductal adenocarcinoma, cholangiocarcinoma and ampul-
lary adenocarcinoma (Fig. 2) (P = 0.014). In the 80 years and older
age group, nearly 44% of the patients died within the first year,
Table 2 Comparison of the pathological findings for the entire
cohort (% in brackets)
Characteristics Total Younger
than 70
years
Older than
70 years
P-value
(n = 428) (n = 309) (n = 119)
Malignant
histopathology
Ductal
adenocarcinoma
85 56 (18) 29 (24) 0.057
Cholangiocarcinoma 60 42 (14) 18 (15)
Ampullary carcinoma 58 36 (12) 22 (18)
IPMN 34 23 (7) 11 (9)
Neuroendocrine 30 27 (9) 3 (3)
Mucinous cystic
neoplasms
14 7 (2) 7 (6)
Solid
pseudopapillary
8 8 (3) 0 (0)
Duodenal
adenocarcinoma
7 5 (2) 2 (2)
Adenosquamous 6 2 (1) 4 (3)
Acinar cell
carcinoma
6 5 (2) 1 (1)
Other malignant 22 19 (6) 3 (3)
Benign
Histopathology
Chronic pancreatitis 25 24 (8) 1 (1) 0.060
Cystadenomas 20 10 (3) 10 (8)
Groove
pancreatitis
10 10 (3) 0 (0)
Other benign 43 35 (11) 8 (7)
IPMN, intraductal papillary mucinous neoplasm.
Table 3 Tumour characteristics for the entire cohort (% in brackets)
Characteristics Younger than
70 years
Older than
70 years
P-value
Tumour classification
T1 1 (1) 2 (2) 0.275
T2 16 (10) 15 (18) 0.105
T3 122 (79) 57 (70) 0.152
T4 16 (10) 8 (10) 1.000
Node status
N0 31 (20) 20 (24) 0.509
N1 126 (80) 64 (76) 0.509
Resection margins
R0 42 (29) 36 (44) 0.020
R1 102 (69) 45 (56) 0.043
R2 3 (2) 0 (0) 0.554
Table 4 Post-operative course
Postoperative
course
Older than
70 years (119)
Younger than
70 years (309)
P-value
Mortality
Yes 4 8 0.745
No 115 301
Overall complications
Yes 15 65 0.052
No 104 244
Grade of complications
Grade I 0 3
Grade II 5 24
Grade III 6 27
Grade IV 0 3
Grade V 4 8
Post-operative length of stay (days)
Average 19  15.1 21  21.2 0.47
Median 15 (3 to 91) 14 (3 to 144 days)
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Table 5 Adjuvant and palliative chemotherapy for the entire malignant cohort (n = 330)
Chemotherapy Total Younger than 70 years Older than 70 years P-value
n = 89/330 (27.0) n = 65/230 (28.3) n = 24/100 (24.0) 0.509
Adjuvant only 60 45 (19.6) 15 (15.0) 0.355
5FU and FA only 36 13
5FU/FA and Cisplatin 2 0
5FU/FA and Mitomycin 1 0
Gemcitabine only 3 1
Capecitabine only 3 1
Palliative 29 20 (8.7) 9 (9.0) 1.000
Adjuvant 5FU/FA and palliative gemcitabine 4 1
Adjuvant 5FU/FA and palliative Capecitabine 1 1
Adjuvant 5FU/FA and palliative gemcitabine and Cisplatine 1 0
Adjuvant Gemcitabine and palliative gemcitabine and
Cisplatine
1 0
Gemcitabine only 7 4
Gemcitabine and Capecitabine 2 1
Gemcitabine and Cisplatin 3 1
Cisplatin and Eposide 1 0
Modified de Gramont 0 1
Days 0 500 1000 1500 2000 2500 3000 
No. at risk < 70 309 230 130 73 44 26 9 
No. at risk ≥ 70 119 73 39 25 22 10 2 
P < 0.0001
Figure 1 Survival curve comparing all patients 70 years of age and
older undergoing a pancreatic resection compared with patients
younger than 70 years old
Days 0 500 1000 1500 2000 2500 3000 
No. at risk < 60 167 126 63 31 18 10 4 
No. at risk 60-69 102 65 36 25 22 11 3 
No. at risk 70-79 143 105 69 43 27 17 6 
No. at risk >80 16 9 5 2 1 0 0 
P = 0.014
days
Figure 2 Survival curve comparing all patients divided into four
groups, younger than 60 years old, 60 to 69 years old, 70 to 79 years
old and older than 80 years old that underwent a pancreatic resec-
tion for ductal adenocarcinoma, Cholangiocarcinoma and ampullary
adenocarcinoma
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beyond which the survival curve was similar to those aged 70 to
79 years.
In patients undergoing pancreatic resection for ductal adeno-
carcinoma, cholangiocarcinoma and ampullary adenocarcinoma,
long-term survival was compared (Fig. 3a–c) between patients
younger than 70 years and those 70 years or older. There was a
significant difference in survival with relation to age in the ductal
adenocarcinoma (P = 0.043) and cholangiocarcinoma (P = 0.003)
groups but not for the ampullary adenocarcinoma category
(P = 0.194) as shown in Fig. 3.
(a)
(c)
(b)
P = 0.043
days
days
days
Younger than 70 years 
Older than 70 years   
P = 0.003
Younger than 70 years 
Older than 70 years   
P = 0.194 
Younger than 70 years 
Older than 70 years   
Days 0 500 1000 1500 2000 2500 3000 
No. at risk < 70 54 31 17 10 8 5 2 
No. at risk ≥70 29 12 7 5 4 2 0 
Days 0 500 1000 1500 2000 2500 3000 
No. at risk < 70 42 30 18 9 3 2 1 
No. at risk ≥70 18 10 2 2 1 0 0 
Days 0 500 1000 1500 2000 2500 3000 
No. at risk < 70 36 25 15 10 6 2 1 
No. at risk ≥70 21 18 11 6 5 1 0 
Figure 3 Survival curves comparing all patients 70 years of age and older undergoing a pancreatic resection for ductal adenocarcinoma
compared wuth patients younger than 70 years old
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Discussion
The results of this study show that the risk of developing pancre-
atic and peri-ampullary malignancy dramatically increases with
age.4 As a result, the epidemiology of the disease combined with
the growth of the older population results in an increasing
number of elderly patients eligible for a pancreatic resection. In
spite of the limited survival benefit of surgery, a pancreaticoduo-
denectomy with or without adjuvant chemotherapy remains the
standard treatment in the absence of other effective treatment
modalities.19
In the last three decades the mortality rates after a pancreatic
resection for benign and malignant periampullary and pancreatic
diseases have dropped to less than 2% at experienced cen-
tres.6,14,20,21 However, a pancreatic resection still carries a signifi-
cant risk with reported morbidity rates exceeding 30%.6 Recently,
centres in America and Europe started to report their results after
pancreatic surgery in the elderly.8–12,20 The age groups studied vary
among the studies. The majority of the studies report statistically
higher morbidity rates in the older group compared with the
younger patients.9,11,14 Some reports demonstrated that the differ-
ence between younger and older groups are not statistically sig-
nificant.9,10,12,14 Interestingly, Brozetti et al. have reported
statistically significant higher rates of mortality among the elderly
group.11
While considerable discussion exists in published literature
about outcome in the elderly, the results have been very varied
with widespread inconsistency as a result of the different age
groups compared. This study not only compares outcome in all
pancreatic resections but also breaks it down into age groups with
benign and malignant subgoups. The current results showed a
significantly lower median survival in the 70 years and older
(57.3 months) compared with 78.7 months in the younger cohort,
although this was for all benign and malignant patients pooled
together. Such a comparison of overall survival is evidently influ-
enced by the significant differences in age between the two groups
(younger than 70 years old and older than 70 years old), in addi-
tion to the higher percentage of patients in the younger group
undergoing resection for benign disease (25.6%), as compared
with 16.0% of patients undergoing resection for benign disease in
the older group.
This study demonstrates that major curative pancreatic resec-
tion in selected elderly healthy patients with pancreatic cancer can
be carried out with satisfactory short-term outcomes. The overall
operative morbidity (10%) and mortality (3.4%) rates are some-
what lower than previously reported results with resection in
patients of all ages but these are for all pancreatic resections,
benign or malignant (although 70% of resections were for malig-
nancy in the elderly cohort). These factors must be considered
when contemplating resection in the elderly; nevertheless, surgical
resection is the only potential procedure offering long-term
survival in the elderly with malignant pancreatic lesions.22,23 The
reluctance to undertake radical resections in the elderly has
diminished with time but the feeling always has been that geriatric
patients tolerate resection less well than younger patients. Further-
more, while the overall survival after pancreatic resections for
malignant lesions has not increased significantly, in the elderly
patients, this study shows that to be just over 20% at 5 years
although the long-term survival is significantly better in the
younger age group as shown in Fig. 2.
While the post-operative mortality as demonstrated in this
study is not significantly higher in the elderly patients there is still
significant morbidity from such major surgery. There may not be
much of a difference in the disease-free survival but the overall
survival is significantly lower in the elderly patients especially the
octogenarians. Another factor to consider is that the elderly
patients are less likely to tolerate chemotherapy and the dro-
pout rates will be higher with the significant age-related
co-morbidities. Not surprisingly this study showed that a greater
number of younger patients underwent chemotherapy (adjuvant
or palliative).
First-line treatment of metastastic pancreatic adenocarcinoma
discussed at the ASCO 2011 showed that the progress in treatment
of pancreatic cancer has been disappointing for decades. Even
with the use of gemcitabine with other anti-metabolites still shows
a median survival of around 12 months at best.24 The median
survival in those70 years after any resection in the present study
was 57.3 months, and 26.5, 16.3 and 47.1 months for patients
70 years with ductal adenocarcinoma, cholangiocarcinoma and
ampullary adenocarcinoma, respectively. Non-resective surgical
palliation in these patients would have prevented this possibility
for prolonged survival.
A limitation of this study is the absence of health-related quality
of life assessments which the unit is currently recording prospec-
tively but there was no available data for this retrospective analy-
sis. The improvement in management of pancreatic cancer in
specialist high volume centres together with improved intensive
care has led to an overall reduction in post-operative mortality.
Unfortunately there are limited data available in the literature
with relation to where the patients go after hospital discharge,
whether it is to their homes, intermediate care facilities such as
rest homes or to residential or nursing home with a lot of assist-
ance required. These data are significant in the elderly population
as quality of life should be a significant determining factor when
making the decision to resect in these patients as although the
mortality has improved the morbidity remains high. Shat et al., in
a recent population study in North America, showed in a cohort of
nearly 50 000 patients, that while mortality after pancreatic
surgery for malignancy decreased from 7.1% to 5.2%, the number
of patients needing assistance at home after discharge increased
from 20% to 33% and the number of patients discharged to
another facility trebled from 5.2% to 13.3%.25 These numbers
were for the entire age range, but without doubt the elderly
population will need the most assistance.
Currently age alone is not a contra-indication for pancreatic
surgery. However, the low survival rates make decisions regarding
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surgery in the elderly population very difficult, when the expected
average lifespan has been reached. However, anecdotally the
authors are more aggressive with younger patients who have sig-
nificant comorbidities. Elderly patients tend to have rigorous
selection criteria applied. Every elderly patient should be selected
for surgery on their own merit; unless the patient’s performance
status is so poor, all elderly patients should have the opportunity
to discuss the risks and benefits of major pancreatic resection with
the operating centre.
This study picked a cut-off age value of 70 years as our numbers
of resections in octogenarians were too few (n = 16) to draw any
significant conclusions.While early recurrence remains a problem
occurring in approximately 20% of all resections, the present
results showed that 44% of patients aged 80 years and over under-
going pancreatic resections for malignancy died in the first year. If
this cohort of early recurrence could be pre-operatively defined,
then the decision to take an elderly patient to surgerymay be easier.
With the continued increase in the geriatric population and
increased incidence of pancreatic cancer in the elderly, and with
the increasing overall incidence of pancreatic cancer over the last
several decades, appropriate treatment of elderly patients with a
pancreatic neoplasm becomes an important consideration.
Results from this study support the contention that age alone
should not necessarily be a limiting factor for a potentially cura-
tive pancreatic resection but rigorous selection criteria has to be
applied in the octogenarian subgroup where results from the
present study have shown significantly poor results with relation
to survival.
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